TrevenaLogo.jpg
Trevena, Inc. Announces Presentations Highlighting Novel S1P1 Receptor Modulator at the American College of Neuropsychopharmacology 59th Annual Meeting
10 déc. 2020 08h43 HE | Trevena Inc.
-- Presentations highlight efficacy of TRV045 in animal models of neuropathic pain and epilepsy TRV045 selectively targets the S1P1 receptor without associated lymphopenia IND filing on track for...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx to Present at Upcoming Investor Conferences
19 févr. 2020 08h37 HE | Aptinyx Inc.
EVANSTON, Ill., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option
14 janv. 2020 16h01 HE | Aptinyx Inc.
EVANSTON, Ill., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx to Present at 38th Annual J.P. Morgan Healthcare Conference
12 déc. 2019 07h07 HE | Aptinyx Inc.
EVANSTON, Ill., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
AptinyxLogo_FullColor_RGB.jpg
Aptinyx to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
30 sept. 2019 07h03 HE | Aptinyx Inc.
EVANSTON, Ill., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
AptinyxLogo_FullColor_RGB.jpg
Three Recent Preclinical Publications Highlight NMDA Receptor Activation Facilitated by Aptinyx’s NYX-2925
26 sept. 2019 08h07 HE | Aptinyx Inc.
EVANSTON, Ill., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Genetimes Technology Named as NanoInk's New Distributor in China
15 janv. 2013 09h30 HE | NanoInk
CHICAGO, IL--(Marketwire - Jan 15, 2013) - NanoInk's NanoFabrication Systems Division is pleased to announce that it has reached a non-exclusive agreement with Genetimes Technology Inc. to serve as...
Southern Connecticut State University Expands Leadership in Nanoscience Education With NanoProfessor Program
24 sept. 2012 09h30 HE | NanoProfessor
SKOKIE, IL--(Marketwire - Sep 24, 2012) - NanoProfessor®, the global leader in hands-on undergraduate nanotechnology education, announced today that Southern Connecticut State University...
Emory University Leverages NanoInk's Dip Pen Nanolithography to Quantify Forces Exerted by Single Receptor Molecules
26 juin 2012 11h24 HE | NanoInk
CHICAGO, IL--(Marketwire - Jun 26, 2012) - NanoInk's NanoFabrication Systems Division is pleased to announce that Emory University recently purchased a Dip Pen Nanolithography® (DPN®)...
Forsyth Tech Expands Nanotechnology Educational Leadership in North Carolina Through NanoProfessor Nanoscience Education Program
04 juin 2012 09h30 HE | NanoProfessor
SKOKIE, IL--(Marketwire - Jun 4, 2012) - NanoProfessor®, a division of NanoInk, Inc.® focused on nanotechnology education, announced today that Forsyth Technical Community College...